Renewed funding paves way for implementation of Consortium’s access programme

The Pediatric Praziquantel Consortium (PPC) has received renewed funding from the Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership (EDCTP) for the implementation of its access programme, ADOPT, to prepare for the large-scale delivery of a new child-friendly medication to treat schistosomiasis in preschool-aged children.

SCI Foundation as a member of the PPC, is co-leading the ADOPT programme.

The project has progressed to Phase III, with a pivotal trial being run in Kenya and Ivory Coast to generate confirmatory data for registration. Through its ADOPT program, the Consortium aims to identify approaches to ensure widespread acceptance and equitable access to its pediatric treatment across endemic countries, once registered.

Read the Consortium’s press release here.

More information about ADOPT here.